biostudies-literatureUnknown27(11)Anker MSDeutsches Zentrum für Herz-KreislaufforschungGerman Centre for Cardiovascular Research<h4>Aims</h4>Cardiac wasting-associated cardiomyopathy in patients with advanced cancer is characterized by loss of left ventricular (LV) mass and independently associated with poor prognosis. Better understanding of this very prevalent cardiomyopathy is urgently needed.<h4>Methods and results</h4>Overall, 398 patients with active, mostly advanced cancer without significant cardiovascular disease (mean LV ejection fraction [LVEF] 64.3 ± 0.2%) or active infection were prospectively examined (mean age 60 ± 1 years, 50% women, body mass index 25.0 ± 0.2 kg/m², 26% cachectic). Patients were categorized and compared by quartiles of LV mass/height². LVEF, global longitudinal strain (GLS), and anticancer therapy naive status were similar across quartiles. Patients in Q1 (lowEuropean journal of heart failure2130-2140https://www.ebi.ac.uk/biostudies/studies/S-EPMC12765034biostudies-literatureClinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer.PMC12765034Zeller TLandmesser UModest DPPorthun JBuchmann NAnker MSBullinger LAttanasio PArshad MSHadzibegovic SRieger KRassaf TTocchetti CGWilkenshoff UButler JLena Avon Haehling SKeller UCleland JGFKhan MSHella JLWitkowski MTotzeck MNikolski AAhn JKretzler LMahabadi AAKarakas MfalseClinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer.<h4>Aims</h4>Cardiac wasting-associated cardiomyopathy in patients with advanced cancer is characterized by loss of left ventricular (LV) mass and independently associated with poor prognosis. Better understanding of this very prevalent cardiomyopathy is urgently needed.<h4>Methods and results</h4>Overall, 398 patients with active, mostly advanced cancer without significant cardiovascular disease (mean LV ejection fraction [LVEF] 64.3 ± 0.2%) or active infection were prospectively examined (mean age 60 ± 1 years, 50% women, body mass index 25.0 ± 0.2 kg/m², 26% cachectic). Patients were categorized and compared by quartiles of LV mass/height². LVEF, global longitudinal strain (GLS), and anticancer therapy naive status were similar across quartiles. Patients in Q1 (low2025-01-01T00:00:00Z2025 Nov2026-06-06T10:24:20.299Z2026-05-28T03:13:25.832ZS-EPMC127650344076738910.1002/ejhf.3744